BioCentury
ARTICLE | Clinical News

Boston Biomedical reports updated data from Phase Ib/II trial of amcasertib in solid tumors

June 30, 2017 6:56 PM UTC

The Boston Biomedical Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) reported updated data from 14 patients with advanced adenoid cystic carcinoma (ACC) in an expansion cohort of the Phase Ib/II BBI503-101 trial showing that once- or twice-daily oral amcasertib (BBI503, BB503) led to 12 cases of stable disease at 8 weeks and 8 cases of disease control for ≥6 months. Median overall survival (OS) was 27.8 months and median progression-free survival (PFS) was 6.1 months.

In 21 patients with squamous cell carcinoma of the head and neck (SCCHN) or salivary or parotid gland cancers in a separate expansion cohort in the trial, amcasertib led to a median OS of 7 months, 12-month survival rate of 38% and median PFS of 1.9 months. Data were presented at the American Society of Clinical Oncology meeting in Chicago...